Stimulation of forward locomotion by SCH-23390 and raclopride in d-amphetamine-treated rats

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 357, Issue 6, 1998, Pages 593-599

  Salmi, Peter ^a   Malmgren, Kristina ^a   Svensson, Torgny H ^a   Ahlenius, Sven ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b Research and Development at Scania Technical Centre   (Sweden)

Author keywords

d Amphetamine; Dopamine receptors; Locomotor activity; Raclopride; Rat; SCH 23390

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; AMPHETAMINE; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR; PRAZOSIN; RACLOPRIDE;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DOPAMINE BRAIN LEVEL; DOSE RESPONSE; LOCOMOTION; MALE; NONHUMAN; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; ANIMALS; DEXTROAMPHETAMINE; DOPAMINE ANTAGONISTS; DOPAMINE UPTAKE INHIBITORS; EXPLORATORY BEHAVIOR; HALOPERIDOL; MALE; MOTOR ACTIVITY; RACLOPRIDE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; SALICYLAMIDES; STIMULATION, CHEMICAL;

EID: 0031806449     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00005213     Document Type: Article

References (35)

1. Ahlenius S (1974) Reversal by L-DOPA of the suppression of locomotor activity induced by inhibition of tyrosine-hydroxylase and DA-β-hydroxylase in mice. Brain Res 69:57-65
2. Ahlenius S (1991) Pharmacological evaluation of new antipsychotic drugs. In: Willner P (ed) Behavioral models in psychopharmacology. Cambridge University Press, Cambridge, pp 311-330
3. Ahlenius S (1992) Effects of the local application of 3-PPP and sulpiride enantiomers into the nucleus accumbens or into the ventral tegmental area on rat locomotor activity: evidence for the functional importance of somato-dendritic autoreceptors. Naunyn-Schmiedeberg's Arch Pharmacol 345:516-522
4. Andén N-E, Grabowska-Andén M (1987) Increased motor activity following combined stimulation of B-HT 920-sensitive and D-1 dopamine receptors. Acta Physiol Scand 131:157-158
5. Andén N-E, Strömbom U, Svensson TH (1973) Dopamine and noradrenaline receptor stimulation: reversal of reserpine-induced suppression of motor activity. Psychopharmacology 29:289-298
6. Arnt J (1995) Differential effects of classical and newer antipsychotics on the hypermotility induced by two dose levels of d-amphetamine. Eur J Pharmacol 283:55-62
7. 1 receptor agonists and antagonists. J Neurochem 48:824-831
8. Braun AR, Chase TN (1986) Obligatory D-1/D-2 receptor interaction in the generation of dopamine agonist related behaviors. Eur J Pharmacol 131:301-306
9. Carlsson A (1970) Amphetamine and brain catecholamines. In: Costa E, Garattini S (eds) Amphetamines and related compounds. Raven Press, New York, pp 289-300
10. Carlsson A (1988) The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1:179-186
11. 2-adrenoreceptor antagonists differentially influence locomotor and stereotyped behaviour induced by d-amphetamine and apomorphine in the rat. Psychopharmacology 96:521-527
12. Ericson E, Samuelsson J, Ahlenius S (1991) Photocell measurements of rat motor activity. J Pharmacol Methods 25:111-122
13. Fischer JF, Cho AK (1979) Chemical release of dopamine from striatal homogenates: evidence for an exchange diffusion model. J Pharmacol Exp Ther 208:203-209
14. Hillegaart V, Ahlenius S (1987) Effects of raclopride on exploratory locomotor activity, treadmill locomotion, conditioned avoidance behavior and catalepsy in rats: Behavioral profile comparisons between raclopride, haloperidol and preclamol. Pharmacol Toxicol 60:350-354
15. Iorio LC, Barnett A, Leitz FH, Houser VP, Korduba CA (1983) SCH 23390, a potential benzazepine antipsychotic with unique interactions on dopaminergic systems. J Pharmacol Exp Ther 226:462-468
16. Jackson DM, Hashizume M (1986) Bromocriptine induces marked locomotor stimulation in dopamine-depleted mice when D-1 receptors are stimulated with SKF 38393. Psychopharmacology 90:147-149
17. 3H]-raclopride: A potent substituted benzamide drug with high affinity for dopamine D-2 receptors in the rat brain. Biochem Pharmacol 34:2251-2259
18. Randrup A, Munkvad I (1970) Biochemical, anatomical and psychological investigations of stereotyped behavior induced by amphetamines. In: Costa E, Garattini S (eds) Amphetamines and related compounds. Raven Press, New York, pp 695-713
19. Salmi P, Karlsson T, Ahlenius S (1994) Antagonism by SCH 23390 of clozapine-induced hypothermia in the rat. Eur J Pharmacol 253:67-73
20. 1 receptor agonist. Eur J Pharmacol 307:27-31
21. Salmi P, Svensson TH, Ahlenius S (1995) d-Amphetamine-induced abnormal behavior in the rat antagonized by SCH 23390 or raclopride. Eur Neuropsychopharmacol 5:332
22. Santiago M, Westerink BH (1991) The regulation of dopamine release from nigrostriatal neurons in conscious rats: the role of somatodendritic autoreceptors. Eur J Pharmacol 204:79-85
23. Schiörring E (1971) Amphetamine induced selective stimulation of certain behaviour items with concurrent inhibition of others in an open-field test with rats. Behaviour 39:1-17
24. 2/3 receptor agonists and antagonists. Neuropharmacology 30:1269-1274
25. Seeman P (1995) Dopamine receptors: clinical correlates. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology: the fourth generation of progress. Raven Press, New York, pp 295-302
26. Seiden LS, Sabol KE, Ricaurte GA (1993) Amphetamine: Effects on catecholamine systems and behavior. Annu Rev Pharmacol Toxicol 32:639-677
27. Siegel S (1956) Non-parametric statistics for the behavioral sciences. McGraw-Hill, New York
28. Stamford JA, Kruk ZL, Millar J (1988) Actions of dopamine antagonists on stimulated striatal and limbic dopamine release: an in vivo voltammetric study. BrJ Pharmacol 94:924-932
29. Svensson TH, Waldeck B (1969) On the significance of central noradrenaline for motor activity: experiments with a new dopamine-β-hydroxylase inhibitor. Eur J Pharmacol 7:278-282
30. Waddington JL (1989) Functional interactions between D-1 and D-2 dopamine receptor systems: their role in the regulation of psychomotor behaviour, putative mechanisms and clinical relevance. J Psychopharmacol 3:54-63
31. Wadenberg M-L, Ahlenius S, Svensson TH (1993) Potency mismatch for behavioral and biochemical effects by dopamine receptor antagonists: implications for the mechanism of action of clozapine. Psychopharmacology 110:273-279
32. Wall SC, Gu H, Rudnick G (1995) Biogenic amine flux mediated by cloned transporters stably expressed in cultured cell lines: Amphetamine specificity for inhibition and efflux. Mol Pharmacol 47:544-550
33. 2/3 Dopamine receptor mRNA in rat brain. Proc Natl Acad Sci USA 88:1859-1863
34. Winer BJ (1971) Statistical principles in experimental design. McGraw-Hill, New York
35. 2/3 dopamine receptors in the basal ganglia of the rat: light and electron microscopy. Neuroscience 65:709-730